National Jewish Health
Quick facts
| Founded | 1899 |
|---|
Marketed products
- Beclomethasone dipropionate HFA · Respiratory/Pulmonology
Beclomethasone dipropionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator release. - budesonide and formoterol
Budesonide reduces inflammation, while formoterol relaxes airway muscles, together improving symptoms of COPD and asthma. - fluticasone propionate and salmeterol · Respiratory/Pulmonology
Fluticasone propionate (an inhaled corticosteroid) reduces airway inflammation while salmeterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing. - Ipratropium/albuterol · Respiratory/Pulmonology
Ipratropium is an anticholinergic bronchodilator that blocks muscarinic receptors to relax airway smooth muscle, while albuterol is a beta-2 agonist that stimulates bronchodilation through a different pathway, providing complementary airway relaxation. - Triple combination therapy
Phase 2 pipeline
- Hymovis · Other
- mycobacteriophage · Infectious Disease
Phase 1 pipeline
- Lipopolysaccharides · Other
- Saracatinab · Other
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about National Jewish Health
What are National Jewish Health's marketed drugs?
Top marketed products include Beclomethasone dipropionate HFA, budesonide and formoterol, fluticasone propionate and salmeterol, Ipratropium/albuterol, Triple combination therapy.
When was National Jewish Health founded?
National Jewish Health was founded in 1899.
Related
- Beclomethasone dipropionate HFA · Respiratory/Pulmonology
- budesonide and formoterol
- fluticasone propionate and salmeterol · Respiratory/Pulmonology
- Ipratropium/albuterol · Respiratory/Pulmonology
- Triple combination therapy
- Sector hub: All tracked pharma companies